Literature DB >> 32646615

Health Economic and Health Service Issues of Palliative Radiotherapy.

M Barton1, V Batumalai2, K Spencer3.   

Abstract

Palliative radiotherapy (PRT) makes up about half of all courses delivered in radiotherapy departments. It is effective in the management of common complications of cancer and is relatively inexpensive. About one third of cancer patients receive PRT within the last 2 years of life. One quarter of all patients who receive radiotherapy will undergo a second or subsequent course, mostly for palliative indications. There is considerable variation in practice, both within and between jurisdictions. This has been attributed to inconsistencies in guidelines, physician variation and differing financial incentives. Because of the widespread use of hypofractionation, variation in PRT fractionation has a lower effect on departmental capacity than variation in radical and adjuvant treatments. Excessive fractionation places an unnecessary burden on frail patients at the end of their lives and uses scarce healthcare resources. With appropriate case selection, the increased cost of fractionation or more conformal treatments can be justified where clinical benefit is expected.
Copyright © 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cost; cost-effectiveness; palliative radiotherapy; variation in practice

Mesh:

Year:  2020        PMID: 32646615     DOI: 10.1016/j.clon.2020.06.013

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  2 in total

1.  The Evolving Practice of Palliative Radiotherapy.

Authors:  A Rembielak; K Dennis
Journal:  Clin Oncol (R Coll Radiol)       Date:  2020-08-20       Impact factor: 4.126

2.  Evaluation of results and costs of high precision radiotherapy (VMAT) compared with conventional radiotherapy (3D) in the treatment of cancer patients with spinal cord compression of metastatic origin.

Authors:  Jon Cacicedo; Elisa Gómez Inhiesto; Maria Teresa Acaiturri Ayesta; Iker Ustarroz; Dirk Rades
Journal:  Rep Pract Oncol Radiother       Date:  2022-09-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.